Ben Chetrit, Nir

Publications

Sort by

Co-Author Network

selected publications

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference. Oncoimmunology. 2025 Conference Paper GET IT
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. 2025 GET IT
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. 2024 GET IT
Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization. 2023 GET IT
Integration of whole transcriptome spatial profiling with protein markers. Nature biotechnology. 2023 Academic Article GET IT
Times cited: 104
Mouse Modeling Dissecting Macrophage-Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2022 Academic Article GET IT
Times cited: 34
Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy. Scientific reports. 2019 Academic Article GET IT
Times cited: 29
Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer. PloS one. 2017 Academic Article GET IT
Times cited: 32
Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. Nature cell biology. 2017 Academic Article GET IT
Times cited: 222
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix. Cancer research. 2016 Academic Article GET IT
Times cited: 103
EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science signaling. 2015 Academic Article GET IT
Times cited: 57
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO molecular medicine. 2015 Academic Article GET IT
Times cited: 38
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science signaling. 2015 Academic Article GET IT
Times cited: 54
Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. Nature communications. 2014 Academic Article GET IT
Times cited: 47
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature communications. 2014 Academic Article GET IT
Times cited: 59
Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration. PloS one. 2013 Academic Article GET IT
Times cited: 16
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 98
ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell adhesion & migration. 2012 Comment GET IT
Times cited: 11
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2011 Academic Article GET IT
Times cited: 87
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene. 2011 Academic Article GET IT
Times cited: 88
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene. 2011 Academic Article GET IT
Times cited: 33
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene. 2011 Academic Article GET IT
Times cited: 30
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene. 2010 Academic Article GET IT
Times cited: 18
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nature cell biology. 2007 Academic Article GET IT
Times cited: 165

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Harnessing Innate Immunity and Radiotherapy for Next-Generation Immuno-Oncology in Metastatic Breast Cancer awarded by METAvivor Research and Support, Inc. Principal Investigator 2025 - 2027
Extending the survival of HR+ breast cancer patients receiving CDK4/6 inhibitors by targeting IL17-producing gamma delta T cells awarded by United States Department of Defense Principal Investigator 2022 - 2026

Dynamics of Immune Response in Irradiated Rectal Cancer awarded by National Cancer Institute Co-Investigator 2022 - 2027

more ...

less ...

Background

education and training

Ph.D., Weizmann Institute of Science (Israel) 2013
M.Sc., Weizmann Institute of Science (Israel) 2008
B.Sc., Hebrew University (Israel) 2006

Contact

full name

Nir Ben Chetrit

primary email

nib2033@med.cornell.edu

VIVO Weill Cornell Medical College

Nir Ben Chetrit Assistant Professor of Radiation Biology in Radiation Oncology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email